key: cord-1025769-rh9bx841
authors: nan
title: Acknowledgement to Referees
date: 2021-10-15
journal: Am J Cardiovasc Drugs
DOI: 10.1007/s40256-021-00507-4
sha: f58cb9d947872b2bcb5842bb768a2ac22ee8bb91
doc_id: 1025769
cord_uid: rh9bx841

nan

The high quality of content published in the American Journal of Cardiovascular Drugs has been reflected in the most recent impact factor of 3.571 (placing the journal in the 2nd quartile of the 'Cardiac & Cardiovascular Systems' category) and CiteScore™ of 5.1. (placing the journal in the top quartile of the 'Cardiology and Cardiovascular Medicine' category). Further, the American Journal of Cardiovascular Drugs has published content in a timely manner, with an average time from submission to first decision of 27 days.

The COVID-19 pandemic has continued to present many challenges and I would like to thank all who have contributed to ensuring the journal has thrived despite the ongoing issues.

I would like to start by thanking the authors of the articles published in the American Journal of Cardiovascular Drugs over the course of 2021. The enthusiasm of all authors for their chosen fields and their willingness to contribute content to the journal are crucial for its continued success.

The quality of published articles is also testament to the diligence of the peer reviewers. I would like to acknowledge the following individuals who acted as reviewers for the American Journal of Cardiovascular Drugs in the last 12 months:

In terms of other important company initiatives, the Springer Nature 'Sustainable Development Goals (SDG) Programme' is aiming to connect researchers who are tackling the world's toughest challenges with practitioners in policy and business, while the 'Women in Science' initiative aims to help empower more women scientists to achieve scientific excellence. Finally, I am delighted to inform you that Springer Nature is now carbon neutral for its direct operations (offices, fleet and flights) and earlier this year signed The Climate Pledge, making a commitment to be Net Zero carbon by 2040.

Returning to the American Journal of Cardiovascular Drugs, the editorial program for 2022 is well under way, and I am looking forward to bringing you many high-quality and authoritative articles in the field of cardiovascular therapy over the coming year. I thank you for your continued support.

With best wishes,

Editor

Springer Nature has continued to support the global response to COVID-19 by making all relevant content immediately and freely available

Impact of the COVID-19 Pandemic on Global Anticoagulant Sales: A Cross-Sectional Analysis Across 39 Countries

The Association Between the Use of Statins and Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-analysis

Treating Acute Decompensated Heart Failure in Patients with COVID-19 Using Intravenous Nitroglycerin in 5% Glutathione